Choose your own adventure: A) give chemotherapy alone and hope the tumor gets the memo, or B) add nivolumab, which is basically handing your immune cells a badge, a flashlight, and permission to stop being politely ignored. CheckMate 649 just followed that second path for five years in advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma, and the long view is the part that makes the pipette hand pause mid-air.
These cancers sit in one of the body’s busiest neighborhoods: the stomach-esophagus border, where acid, food, inflammation, and a lifetime of cellular paperwork all mingle. When cancer shows up there and has already become unresectable or metastatic, treatment gets tough fast. Historically, first-line chemotherapy has been the main workhorse. It can shrink tumors, but it often feels like asking a leaf blower to do surgery: useful, forceful, not exactly subtle.
The Checkpoint Bouncer
Nivolumab blocks PD-1, a checkpoint receptor on immune cells. PD-1 normally helps prevent immune overreaction, which is great when your immune system is deciding whether to attack pollen or your pancreas. Tumors, being the cellular rebels who read the policy manual for loopholes, can exploit this pathway by using PD-L1 signals to tell T cells, “Nothing to see here.”
PD-L1 combined positive score, or CPS, tries to measure how much of that “please ignore me” signaling exists in the tumor neighborhood. It counts PD-L1 staining in tumor and immune cells relative to tumor cells. Is it a perfect biomarker? Absolutely not. If biomarkers were perfect, half of translational oncology would lose its favorite source of conference hallway arguments. But CPS helps identify patients more likely to benefit from PD-1 blockade.
Five Years Is a Long Time in Metastatic Cancer
In the new five-year follow-up of CheckMate 649, adults with previously untreated, HER2-negative, unresectable advanced or metastatic gastroesophageal adenocarcinoma received either nivolumab plus chemotherapy or chemotherapy alone. Among patients with PD-L1 CPS of 5 or higher, the combination kept its survival advantage after a minimum follow-up of 60.1 months: overall survival hazard ratio 0.71, and progression-free survival hazard ratio 0.71.
Translated out of trial-speak: the combo did not just win the early sprint and then collapse behind the poster board. At five years, 16% of patients in the nivolumab-plus-chemo group were alive versus 6% with chemotherapy alone. Progression-free survival at five years was 10% versus 6%. Those numbers are still sobering, but in advanced gastroesophageal cancer, moving the long-term tail of the curve matters. That tail is where real people get birthdays, scans that do not ruin the week, and maybe enough normal life to complain about parking again.
The response rate also favored the combination: 58% versus 46%, with a median duration of response of 8.5 months versus 6.9 months. Anyone who has spent three months optimizing an antibody dilution only to get a Western blot that looks like a weather map will appreciate this: durable signal is the dream.
The Catch, Because Biology Charges Rent
The benefit came with more toxicity. Grade 3 or 4 treatment-related adverse events occurred in 60% of patients receiving nivolumab plus chemotherapy versus 45% with chemotherapy alone. The study reported no new safety concerns after long follow-up, which is comforting, but “acceptable safety” in oncology still means clinicians and patients need to watch closely for immune-mediated side effects, infections, neuropathy, fatigue, and the general indignities of multi-drug treatment.
This is not “nivolumab fixes gastric cancer.” It is “nivolumab plus chemotherapy gives a meaningful subset of patients better odds, especially when PD-L1 CPS is higher.” That distinction matters. Cancer biology loves heterogeneity the way lab freezers love mystery boxes from 2017.
Why This One Sticks
The original CheckMate 649 results helped shift first-line treatment for advanced HER2-negative gastric, gastroesophageal junction, and esophageal adenocarcinoma. Later updates at two and three years suggested the benefit persisted. This five-year analysis strengthens the idea that PD-1 blockade plus chemotherapy can produce a real long-term survival advantage, not just a nicer early Kaplan-Meier curve.
The next challenge is sharper selection. PD-L1 CPS helps, but it is not the whole story. Tumor mutational patterns, microsatellite instability, immune cell infiltration, microbiome effects, and resistance pathways all matter. In plain English: the tumor microenvironment is a sketchy neighborhood, and we still do not know which streetlights are broken.
For patients, the practical message is clear enough to discuss with an oncology team: for eligible PD-L1-positive advanced gastroesophageal adenocarcinoma, nivolumab plus chemotherapy remains a standard first-line option with five-year data behind it. For researchers, the message is less relaxing: keep figuring out who benefits, who gets harmed, and how to make that survival tail less skinny.
References
-
Janjigian YY, Shitara K, Ajani JA, et al. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649. Annals of Oncology. 2026. DOI: 10.1016/j.annonc.2026.02.003
-
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma: CheckMate 649. The Lancet. 2021;398:27-40. DOI: 10.1016/S0140-6736(21)00797-2
-
Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603:942-948. DOI: 10.1038/s41586-022-04508-4
-
Janjigian YY, Ajani JA, Moehler M, et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of CheckMate 649. Journal of Clinical Oncology. 2024;42:2012-2020. DOI: 10.1200/JCO.23.01601
-
Yang J, Li Y, Liu Y, et al. Recent developments in immunotherapy for gastrointestinal tract cancers. Journal of Hematology & Oncology. 2024;17. DOI: 10.1186/s13045-024-01578-x
-
Alsina M, Arrazubi V, Diez M, Tabernero J. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nature Reviews Gastroenterology & Hepatology. 2023;20:155-170. DOI: 10.1038/s41575-022-00703-w
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.